BLX 6000
Alternative Names: BLX-6000; MLX-6000Latest Information Update: 30 Aug 2024
At a glance
- Originator Biolexis Therapeutics
- Class Cardiovascular therapies; Small molecules
- Mechanism of Action Monomeric GTP-binding protein inhibitors; MTORC1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cardiovascular disorders; Metabolic disorders
Most Recent Events
- 30 Aug 2024 Preclinical trials in Cardiovascular disorders in USA (PO) prior to August 2024 (Biolexis Therapeutics pipeline, August 2024)
- 30 Aug 2024 Preclinical trials in Metabolic disorders in USA (PO) prior to August 2024 (Biolexis Therapeutics pipeline, August 2024)
- 17 Apr 2024 Biolexis Therapeutics plans to file an IND application in third quarter of 2025 (Biolexis Therapeutics pipeline, April 2024)